Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Metastatic Urethral Urothelial Carcinoma

Nagoya UniversitySmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Metastatic Urethral Urothelial Carcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
Nagoya University
Phase 3BB
Cyclophosphamide
Alliance for Clinical Trials in Oncology
Phase 3BB
Pembrolizumab
Alliance for Clinical Trials in Oncology
Phase 3BB
Relatlimab
National Cancer Institute (NCI)
Phase 2/3BB
Atezolizumab
Alliance for Clinical Trials in Oncology
Phase 3BB

View all 23 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →